← Search recalls
FDA (Drug enforcement)Recalled 2023-07-17closedclass ii

Central Admixture Pharmacy Services Inc: fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, Rx only, Central Admix

Hazard

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Details from the source

Reason for recall: Lack of assurance of sterility: Lack of validation data for sanitization cycles Distribution: Nationwide in the USA Quantity: 1,486 syringes Lot/code info: Lot: 17-270811, Exp. 7/19/2023; 17-270954, 17-270983, Exp. 7/23/2023; 17-271231, Exp. 7/26/2023; 17-271690, Exp. 8/2/2023; 17-272204, Exp. 8/13/2023; 17-272684, Exp. 8/20/2023; 17-272992, Exp. 8/24/2023; 17-273053, Exp. 8/28/2023; 17-273436, Exp. 9/3/2023.

Source

Official record: FDA (Drug enforcement)

Republished from the official source above; details can change — the source record controls.

Hurt by this product? Start a free Case Check

ProductRisk is not a law firm and does not provide legal services or legal advice. ProductRisk is a free consumer product-safety information service operated by Plaintify, Inc., a technology company. If you ask to be connected with a law firm, any legal services are provided by that firm — not by ProductRisk or Plaintify.

Privacy · Plaintify